



The English text is an unofficial translation. In case of any discrepancies between the Swedish language version of this document and the English translation, the Swedish language version shall prevail.

Bulletin from the annual general meeting in Cyxone AB on 3 June 2021

Today, on 3 June 2021, the annual general meeting was held in Cyxone AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.

Resolution on adoption of accounts and allocation of the company's result

The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual general meeting also resolved in accordance with the proposal from the board of directors to allocate the company's result, meaning that no dividends are paid and that available funds are carried forward.

Discharge from liability for the members of the board of directors and the CEO

The annual general meeting resolved to discharge the members of the board of directors and the CEO from liability for the financial year 2020.

Election and remuneration of the board of directors and auditors

The annual general meeting resolved to re-elect Bert Junno, Theresa Comiskey Olsen, Saad Gilani and Mikael Lindstam as board members, and to elect Peter Heinrich and Alejandra Mørk as new board members. Bert Junno was re-elected as Chairman of the board of directors.

Furthermore, the annual general meeting resolved that board remuneration shall be paid with SEK 450,000 to the Chairman of the board of directors, with EUR 25,000 to the board member Peter Heinrich and with SEK 225,000 to each of the other board members.

Finally, the annual general meeting resolved to re-elect the accounting firm KPMG AB as auditor, and that remuneration for the auditor shall be paid in accordance with approved invoice. KPMG AB has informed that the authorized public accountant Camilla Alm Andersson will continue to be the auditor in charge.

Resolution on authorization for the board of directors to issue new shares, warrants or convertibles with preferential rights for the shareholders or against payment in-kind

The annual general meeting resolved in accordance with the proposal from the board of directors to authorize the board of directors to resolve, on one or several occasions before



the next annual general meeting, to issue new shares, warrants or convertibles with preferential rights for the shareholders or conditional upon payment in-kind. As regards to the preferential issue, the payment may be in cash or through set-off. The total number of shares that may be issued, or, as regards issue of convertibles or warrants, issued by conversion or exercise, under the authorization shall not be limited in any other way than by the limits for the share capital and number of shares, as set forth from time to time in the registered articles of association.

Resolution on authorization for the board of directors to issue new shares, warrants or convertibles with deviation from the shareholders' preferential rights and against payment in cash or through set-off

The annual general meeting resolved in accordance with the proposal from the board of directors to authorize the board of directors to resolve, on one or several occasions before the next annual general meeting, to issue new shares, warrants or convertibles with deviation from the shareholders' preferential rights. Shares, warrants or convertibles may be issued for cash payment or payment through set-off. The total number of shares that may be issued, or, as regards issue of convertibles or warrants, issued by conversion or exercise, under the authorization shall not be limited in any other way than by the limits for the share capital and number of shares, as set forth from time to time in the registered articles of association. An issue adopted on the basis of the authorization, shall be made on market terms (meaning that an issue discount in line with prevailing market conditions may be granted).

Malmö on 3 June 2021

Cyxone AB (publ)

For further information about Cyxone AB, please contact

Tara Heitner, CEO

Tel: +46 70 781 88 08

Email: tara.heitner@cyxone.com

Adelgatan 21

211 22 Malmö, Sweden

The information was submitted for publication, through the agency of the contact person set out above, at 13.55 CET on 3 June 2021.

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com